Rapid developments in gene-modified cell therapies, especially CAR T-cell therapies, has increased demand for fast and reliable analytics methods for research, in-process development, and ...
Emily Whitehead made the history books in 2012 when she become the first pediatric patient with B-cell acute lymphoblastic leukemia to be given a chimeric antigen receptor (CAR) T-cell therapy. After ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results